Hyperglycemia-Associated Liver Cancer: Global Disparities Across Age, Sex, and Development Levels in the 2021 GBD Study
Document Type
Conference Proceeding
Publication Date
10-2025
Publication Title
American Journal of Gastroenterology
Abstract
Introduction: Hyperglycemia is a growing metabolic risk factor for liver cancer, but its burden across age, sex, and socio-demographic index (SDI) levels remains undercharacterized. This study aims to assess liver cancer mortality and disability attributable to hyperglycemia using the 2021 Global Burden of Disease (GBD) Study. Methods: GBD 2021 data were analyzed from 1990–2021 to estimate liver cancer deaths, disability-adjusted life years (DALYs), and years of life lost (YLLs) attributable to hyperglycemia. Trends were stratified by age, sex, and SDI, using Average Annual Percent Change (AAPC) with 95% confidence intervals (CIs). Results: Globally, men experienced a higher burden of liver cancer attributable to hyperglycemia compared to women, with 3.21 million vs 2.83 million DALYs, respectively. The age-adjusted DALY rate increased more rapidly in men than in women (AAPC: 2.94 vs 2.68). Similarly, men had a higher total number of deaths (133,685 vs 131,616), with mortality rates rising more steeply among men (AAPC: 3.26 vs 3.01). The YLLs burden was also greater in men (3.18 million) compared to women (2.81 million), with a faster increase observed in men (AAPC: 2.94 vs 2.67). Age-stratified analysis showed that individuals aged $70 years experienced the most significant rise in DALYs, mortality rates, and YLLs (AAPC: 1.95, 2.13, and 1.95, respectively), followed by the 50–69 age group (AAPC: 1.43, 1.49, and 1.43) and the 15–49 age group (AAPC: 1.37, 1.42, and 1.36). When stratified by SDI, countries in the low-middle SDI category demonstrated the fastest increases in DALY rates (AAPC: 3.87), mortality rates (AAPC: 3.95), and YLLs (AAPC: 3.86), followed by countries in the high and middle SDI categories. Conclusion: The global burden of liver cancer attributable to hyperglycemia has risen substantially over the past 3 decades, with disproportionately higher impacts among men, older adults, and populations in low-middle SDI countries. These findings highlight the urgent need for targeted public health interventions and glycemic control strategies, particularly in high-risk demographic and socioeconomic groups, to mitigate the growing liver cancer burden.
Volume
120
Issue
10S2
First Page
S517
Last Page
S517
Recommended Citation
Ali MF, Singh A, Ahmad H, Sharif A, Bin Hameed U, Moazzam M, et al. [Sharif A]. Hyperglycemia-associated liver cancer: global disparities across age, sex, and development levels in the 2021 GBD Study. Am J Gastroenterol. 2025 Oct;120(10S2):S517. doi:10.14309/01.ajg.0001137080.09849.2a
DOI
10.14309/01.ajg.0001137080.09849.2a

Comments
American College of Gastroenterology Annual Meeting, October 24-29, 2025, Phoenix, AZ